The number of, and interest in, quality of life studies has grown dramatically in the last decade. On an ever increasing basis, patients, clinicians, researchers, and health policy regulators are considering quality of life in assessing treatment alternatives. Unfortunately, most discussions of quality of life are narrow in scope -- applying to only one disease group. This unique book represents the concerted effort of experts in academia, federal government health care regulators, and pharmaceutical industry representatives to define the promise and the problems associated with quality of life studies. The issues covered range from cross cutting ones to those that are specific to particular illnesses. Because quality of life takes into consideration such domains as mood, vocation, family, sexual functioning, social participation, and costs, this book will serve as an invaluable companion to readers with an interest in behavioral medicine research.

The number of, and interest in, quality of life studies has grown dramatically in the last decade. On an ever increasing basis, patients, clinicians, researchers, and health policy regulators are considering quality of life in assessing treatment alternatives. Unfortunately, most discussions of quality of life are narrow in scope -- applying to only one disease group. This unique book represents the concerted effort of experts in academia, federal government health care regulators, and pharmaceutical industry representatives to define the promise and the problems associated with quality of life studies. The issues covered range from cross cutting ones to those that are specific to particular illnesses. Because quality of life takes into consideration such domains as mood, vocation, family, sexual functioning, social participation, and costs, this book will serve as an invaluable companion to readers with an interest in behavioral medicine research.